Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities from May 12, 2014 through November 20, 2015, all dates inclusive (the “Class Period”) of the important January 22, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Osiris investors under the federal securities laws.
To join the Osiris class action, go to the firm’s website at http://rosenlegal.com/cases-786.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action. The case is pending in the U.S. District Court for the Southern District of New York.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-786.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
